Nektar Therapeutics (NKTR)

Market Cap	398.96M
Revenue (ttm)	74.93M
Net Income (ttm)	-122.27M
Shares Out	17.30M
EPS (ttm)	-8.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	914,793
Open	22.59
Previous Close	21.75
Day's Range	22.01 - 23.98
52-Week Range	6.48 - 37.38
Beta	0.96
Analysts	Strong Buy
Price Target	81.67 (+254.16%)
Earnings Date	Aug 7, 2025

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 1994
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTR
• Website: https://www.nektar.com

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price target is $81.67, which is an increase of 254.16% from the latest price.

Price Target

$81.67

(254.16% upside)

Analyst Consensus: Strong Buy